The present invention provides ingestible dosage form articles such as opaque capsules with reduced light transmittance.

A pharmaceutical formulation contains the following components in part by weight: (a) 1 part of the compound represented by Formula (I), ##STR00001## (b) 16 to 600 parts of a meltable and dispersible carrier comprising poloxamer and polyethylene glycol in a poloxamer-to-polyethylene glycol weight ratio of 1-0.5 to 1:27, and (c) 0.2 to 100 parts of a non-volatile weak acid. The pharmaceutical formulation helps to improve the in vitro dissolution of the compound of Formula (I).

The invention relates to developing a novel water and capsule formulation using fenofibrate which is difficult to dissolve and control its release rate in vitro. For example, the invention relates to the creation of capsules and wafers comprising: fenofibrate, a surfactant, a carrier wax, a film former, a plasticizer, and optionally a super disintegrant or other ingredients. The invention further relates to the process of forming such capsules and wafers.

Liquid fill matrices comprising dissolved arsenic trioxide and having not more than 20% aqueous component and at least 80% nonaqueous component, wherein the components are miscible, are described as well as processes of preparing such liquid fill matrices and processing the liquid fill matrices into dosage forms including soft capsules; for the treatment of various ailments, such as cancer and GVHD.

The present invention provides ingestible dosage form articles such as opaque capsules with reduced light transmittance.

The invention discloses opaque capsule shells made from gelatin with ground CaCO.sub.3 as opacifier; and a method for making them.

A method for preparing a water-soluble curcumin mixture with high bioavailability includes the following steps: A) dissolving curcumin, vitamin C and ascorbyl palmitate in an ethanol aqueous solution, evaporating ethanol under reduced pressure, and vacuum drying to obtain a curcumin-vitamin C-ascorbyl palmitate co-crystal; B) high-speed emulsifying the curcumin-vitamin C-ascorbyl palmitate co-crystal and a wall material colloidal solution under vacuum, sequentially conducting a two-stage wet grinding, a homogenization and a potential adjustment to obtain an emulsified body; and C) subjecting the emulsified body to microencapsulation with a wall material twice and drying to obtain the water-soluble curcumin.

The present invention relates to a solid pharmaceutical preparation of 3-Fluoro-4-[7-methoxy-3-methyl-8-(1-methyl-1H-pyrazol-4-yl)-2-oxo-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl]-benzonitrile, a method of making same, and medical uses thereof.

Exemplary embodiments of the disclosure may be drawn to ingestible delivery devices. An ingestible delivery device may include a first compartment and a second compartment. A lipase may be contained within the first compartment, and a fat may be contained within the second compartment. The first compartment may be sealed from the second compartment prior to exposure to a trigger, preventing the lipase and the fat from contacting each other, and at least one of the first compartment or the second compartment may at least partially rupture upon exposure to the trigger, allowing the lipase and the fat to contact each other.

A formulation for vaginal administration comprising an effective amount of a composition of dried Lactobacillus cells and boric acid, with a carrier. The composition can include one or more antioxidants. Optionally, the composition is in a unit dosage form. Also provided are methods for making and using the composition.